Sponsors
The bill broadens FDA and CBER authority to remove unsafe drugs and protect supply chains, improving patient safety but increasing the risk of regulatory-driven product holds, short-term shortages, and uncertainty for drug makers.
Patients (including those with chronic conditions) and healthcare providers will have stronger, faster FDA authority to stop distribution and recall a wider range of drugs (replacing 'controlled substances' with 'drugs'), reducing exposure to unsafe or noncompliant medications.
Hospitals, patients, and supply-chain managers will be better protected because import/export restrictions now apply to a broader set of drugs, helping prevent unsafe or noncompliant drugs from entering U.S. supply chains.
CBER gains explicit authority to issue distribution or recall orders for biologics and vaccines, improving regulatory oversight and the ability to quickly address problems with those products.
Patients (particularly those with chronic conditions) may face interruptions in access if broader authority results in more product holds or recalls, creating a risk of short-term drug shortages.
Manufacturers and distributors could experience broader regulatory disruption and costs from more frequent holds or import bans, which could strain supply chains or raise prices.
Companies producing biologics and vaccines may face uncertainty about enforcement patterns and compliance expectations until agencies issue implementing guidance, complicating planning and operations.
Based on analysis of 2 sections of legislative text.
Replaces the phrase “controlled substances” with the broader term “drugs” in two FDA enforcement provisions, expanding the statutory language that supports orders to stop distribution, recall products, and restrict imports/exports tied to such orders. It also explicitly adds the Director of the Center for Biologics Evaluation and Research (CBER) and officials senior to that Director or the Center for Drug Evaluation and Research Director to the list of officials who may issue these orders. The bill is a narrow statutory amendment: it changes terminology and who is listed as an authorized official in the Federal Food, Drug, and Cosmetic Act provisions that govern distribution/recall orders and related import/export restrictions. It does not create new programs, allocate funds, or impose new federal mandates in the text provided.
Introduced March 18, 2026 by Maxine Dexter · Last progress March 18, 2026